Physician profile
Charles M Boyd
NPI 1871680645
$825,103.11
in general payments reported to CMS, 2019-2025
10 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $108K · 2021: $170K · 2022: $112K · 2023: $91K · 2024: $122K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $165K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Travel and Lodging: $32K · Food and Beverage: $8,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $164,839.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,762.96 |
| Travel and Lodging | $31,788.98 |
| Food and Beverage | $8,768.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $403,900.38 | 2019-2022 | |
| Abbvie INC. | $300,028.11 | 2022-2025 | Botox, Kybella, Natrelle Saline-Filled Breast Implants |
| Galderma Laboratories, L.P. | $116,538.30 | 2019-2025 | Dysport |
| Merz North America, INC. | $3,873.12 | 2019 | |
| Sun Pharmaceutical Industries INC. | $165.16 | 2024 | |
| Medtronic, INC. | $164.77 | 2024 | Propel |
| Revance Therapeutics, INC. | $152.87 | 2024 | Daxxify |
| Ets Wound Care LLC | $148.63 | 2025 | Mirragen Advanced Wound Matrix |
| Mallinckrodt Enterprises LLC | $131.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.